About RenaBio Therapeutics
RenaBio Therapeutics is a private company based in Natick, Massachusetts, incorporated in 2023 in Delaware. It has reported $1,255,000 raised in two offerings on Form D since April 2024. Its chief executive is Shengjun Ren.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 20, 2025 | Feb 26, 2025 | $250,000of $4.1M target | 1 | $250K | EquityRule 506(b) | Form D ↗ |
| Mar 28, 2024 | Apr 3, 2024 | $1,005,000of $4.0M target | 18 | $55,833 | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $1,255,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RenaBio Therapeutics's Form D filed Feb 26, 2025.
ZW
Zhenghua Wang
Director
YZ
Yu (Zoe) Zhang
Director
HB
Hans Bitter
Director
JM
Jafari Mousa
Director
SR
Shengjun Ren
Chief Executive Officer and director